Objective To explore the expression level and clinical significance of α-Arrestin domain-containing protein 3(ARRDC3)gene in human brain glioma tissues.Methods Clinical data and gene expression of patients with brain glioma were analyzed using the Chinese Glioma Genome Atlas(CGGA)database and the Cancer Genome Atlas(TCGA)database.Brain glioma specimens were collected from 9 patients with primary brain gliomas treated in the Department of Neurosurgery,the Affiliated Hospital of Xuzhou Medical University from January 2018 to December 2021.The expression levels of ARRDC3 in gliomas of different grades were detected through immunohistochemical experiments.The expression levels of ARRDC3 in gliomas with different molecular types and grades were analyzed by using thenon-parametrictest.The effect of ARRDC3 expression on the survival time of brain glioma patients was analyzed by using the Kaplan-Meier survival curve,while the effect of ARRDC3 expression on prognosis of glioma patients was analyzed by using univariate and multivariate Cox regression models.Results Data in the CGGA and TCGA databases showed that the expression of ARRDC3 in the grade Ⅱ,Ⅲ and Ⅳhuman brain gliomas increased gradually(P＜0.05).The results of immunohistochemical staining experiments were consistent with the above results(P＜0.05).The ARRDC3 expression in isocitrate dehydrogenase(IDH)wild type glioma patients was significantly higher than that in IDH mutant glioma patients(P＜0.05).The overall survival of the patients with high ARRDC3 expression was significantly shorter than that of the patients with low ARRDC3 expression(P＜0.05).Multivariate Cox regression analysis revealed that age,IDH mutation state,radiotherapy and ARRDC3 expression were risk factors for prognosis of human brain glioma patients(P＜0.05).Conclusion With the pathological grade rising gradually,the relative expression level of ARRDC3 in human brain glioma tissues increases gradually.The prognosis of brain glioma patients with low expression of ARRDC3 is significantly better than that of patients with high expression of ARRDC3.ARRDC3 can be used as a prognostic factor for glioma patients.